10 completed, 3 terminated, 2 active not recruiting, 2 withdrawn. 14 Phase 2, 5 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 6, Terminated 3, Active not recruiting 2, Withdrawn 2, Unknown 1 |
| Phase 1 | 5 | Completed 4, Withdrawn 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Castration Levels of Testosterone: new trials by email Literature Review of Castration Levels of Testosterone trials Research Report on Castration Levels of Testosterone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer Decitabine, Enzalutamide - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 1 / Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2021-04-15 | 2022-10-05 | |
| Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer Apalutamide, Stereotactic Body Radiation Therapy - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Completed | University of California, San Francisco | 26 | 2019-12-17 | 2026-01-21 |
| ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981, Nivolumab - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Terminated | Barbara Ann Karmanos Cancer Institute | 10 | 2019-11-13 | 2024-07-16 |
| sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Recombinant EphB4-HSA Fusion Protein - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Unknown | Northwestern University | 14 | 2019-09-20 | 2022-04-27 |
| Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer Enzalutamide, Venetoclax - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 1 | Completed | Roswell Park Cancer Institute | 10 | 2019-08-02 | 2023-10-16 |
| 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Lutetium Lu 177-PSMA-617, Pembrolizumab - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 1 | Completed | University of California, San Francisco | 43 | 2019-05-10 | 2025-02-25 |
| Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer Abiraterone, Bicalutamide, Degarelix - Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 1273 | 2018-09-24 | 2026-10-08 |
| Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency Carboplatin, Docetaxel, Laboratory Biomarker Analysis - ATM Gene Mutation, BRCA1 Gene Mutation | Phase 2 | Terminated | University of Washington | 18 | 2018-08-24 | 2026-08-26 |
| Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer HER2Bi-Armed Activated T Cells, Laboratory Biomarker Analysis, Pembrolizumab - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 15 | 2018-06-07 | 2023-05-03 |
| Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Durvalumab, Laboratory Biomarker Analysis - Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer | Phase 2 | Withdrawn | University of Washington | 2018-05-15 | 2018-01-17 | |
| Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Abiraterone Acetate, Androgen deprivation therapy, Cabazitaxel - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 223 | 2018-04-26 | 2026-10-06 |
| ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer ESK981 - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 13 | 2018-03-08 | 2023-07-14 |
| Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Abiraterone Acetate, Apalutamide, Cabazitaxel - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 196 | 2016-05-18 | 2026-09-14 |
| Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway Carboplatin, Docetaxel, Laboratory Biomarker Analysis - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Completed | University of Washington | 14 | 2016-01-26 | 2022-11-17 |
| Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer Enzalutamide, Laboratory Biomarker Analysis, Niclosamide - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 1 | Completed | University of Washington | 5 | 2015-12-31 | 2018-04-18 |
| Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer Selinexor - Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer | Phase 2 | Terminated | University of California, San Francisco | 14 | 2014-09-02 | 2018-06-26 |
| CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer Glycosylated Recombinant Human Interleukin-7, Laboratory Biomarker Analysis - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Completed | Fred Hutchinson Cancer Center | 54 | 2013-09-10 | 2019-07-09 |
| Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide Cytology Specimen Collection Procedure, Enzalutamide, Laboratory Biomarker Analysis - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Completed | OHSU Knight Cancer Institute | 41 | 2013-03-12 | 2020-09-28 | |
| Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer Cabazitaxel, Carboplatin, Laboratory Biomarker Analysis - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 170 | 2012-07-11 | 2021-07-30 |
Prostatic Neoplasms (14) · Disease Progression (1) · Lymphadenopathy (1) · Microsatellite Instability (1)
Genital Diseases (14) · Genital Diseases, Male (14) · Genital Neoplasms, Male (14) · Male Urogenital Diseases (14) · Neoplasms (14) · Neoplasms by Site (14) · Prostatic Diseases (14) · Urogenital Diseases (14) · Urogenital Neoplasms (14) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Disease Attributes (1) · Genomic Instability (1) · Hemic and Lymphatic Diseases (1) · Lymphatic Diseases (1)
Carboplatin (4) · enzalutamide (4) · Docetaxel (3) · Prednisone (3) · XRP6258 (3) · cabazitaxel (3) · Abiraterone Acetate (2) · apalutamide (2) · deltacortene (2) · pembrolizumab (2) · prednylidene (2) · 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one (1) · Androgen Antagonists (1) · CTLA-4 Antigen (1) · Castration (1)
University of Washington (4) · Barbara Ann Karmanos Cancer Institute (3) · University of California, San Francisco (3) · M.D. Anderson Cancer Center (2) · Roswell Park Cancer Institute (2) · ECOG-ACRIN Cancer Research Group (1) · Fred Hutchinson Cancer Center (1) · Northwestern University (1) · OHSU Knight Cancer Institute (1) · SWOG Cancer Research Network (1)
United States (19) · Chile (1) · Colombia (1) · Mexico (1) · Puerto Rico (1) · Switzerland (1)
Gurkamal Chatta (2) · Heather H. Cheng (2) · Michael Schweizer (2) · Rahul Aggarwal, MD (2) · Abhinav Deol, M.D. (1) · Ana Aparicio (1) · Brian Chapin (1) · Charles Ryan, MD (1) · Christos Kyriakopoulos (1) · Elisabeth Heath, M.D. (1) · Elisabeth I. Heath (1) · Joshi Alumkal (1) · Lawrence Fong (1) · Maha H Hussain, M.D. (1) · Martin A. Cheever (1)
PMID 29487219, PMID 29856824, PMID 31515154, PMID 35405009, PMID 36210299, PMID 37922930, PMID 37981040, PMID 39227508, PMID 39503807, PMID 41315064
P30CA015704 (4), P30CA022453 (3), P50CA097186 (3), P30CA016672 (1), P30CA060553 (1), R01CA229354 (1), U01CA154967 (1), U10CA180820 (1), U10CA180888 (1)